Neuren Pharmaceuticals
Bienvenido a Neuren Pharmaceuticals (www.neurenpharma.com; ASX: NEU). Neuren es una empresa con sede en Melbourne que esta a la vanguardia de los esfuerzos p
Neuren (NEU) – Anuncio del síndrome de Angelman
15 February 2021 Ensayo exitoso de fase 1 para el NNZ-2591 de Neuren Después de un año de montaña rusa, un medicamento de Angelman se acerca a los pacient
Esperanza en el horizonte para el síndrome de Angelman
EXQUISITE SCIENCE15 de Febrero, 2021 Mary Parker Después de un año de montaña rusa, un medicamento de Angelman se acerca a los pacientes Este año trajo d
Gene Therapy in Angelman Syndrome: Agilis Biotherapeutics
By Allyson Berent, DVM, DACVIM At the annual Foundation for Angelman Syndrome Therapeutics (FAST) Global Summit in December, Jodi Cook, Ph.D., Chief Operat
FAST US and FAST AU Announce Joint Funding To Dr. Arthur Beaudet To Generate Mouse Lines Expressing Human UBE3A Antisense
“Of all the childhood genetic neurologic disorders of the brain, Angelman syndrome may be the single best candidate for developing a definitive treatment (
FAST-Funded Research Leads To $1.1 Million Grant
Additional Gene Therapy Approach For Angelman Syndrome Explored By Paula Evans The Foundation for Angelman Syndrome Therapeutics (FAST) is delighted to annou
Towards Therapeutics – The FIRE Team Series, Part I
Edwin Weeber, Ph.D. is a Professor in the Department of Molecular Pharmacology and Physiology and the Chief Scientific Officer at the University of South Flo
Collaborating for Clinical Trials
Stakeholders meet to develop Biomarkers and Outcome Measures for clinical trials in Angelman Syndrome We are thrilled to announce that the Angelman Syndrome
Ketone esters for the treatment of seizures in AS – clinical trial coming soon!
Medical foods as an effective approach to management of Angelman Syndrome The following is a recount of a presentation about using therapeutic ketones (KES)
The FIRE team of FAST turns on Ube3a in mice with Angelman Syndrome….the future gets even MORE promising with Zinc Finger technology.
Read about the recently published paper “Protein Delivery of an Artificial Transcription Factor Restores Widespread Ube3a Expression in an Angelman Syn